IN THE CLAIMS

1. (currently amended) An anilide derivative~~, characterized in that it corresponds to~~ having the general formula I:



I

~~in which~~wherein:

- R_1 ~~represents~~ is a hydroxyl or amino group;~~,~~
- R_2 ~~represents~~ is a hydrogen or ~~a~~ methyl radical;~~,~~
- R_3 ~~represents~~ is a hydrogen or a fluorine atom; and~~,~~
- ~~A represents a group~~wherein A is

~~:~~a)



~~in which:~~or

~~— n represents an integer from 5 to 11, limits inclusive,~~

~~— R_4 and R_5, which may be identical or different, represent, independently of one another, hydrogen or a fluorine atom~~

~~:~~b)



wherein:

- n is an integer from 5 to 11, limits inclusive, and

R_4 and R_5, are independently a hydrogen or a fluorine atom; and

enantiomers or stereoisomers of said analide derivative, and pharmaceutically acceptable salts thereof.

~~in which n, R_4 and R_5 have the same meaning as above,~~

~~in the form of their various stereoisomers and enantiomers, and mixtures thereof, for the compounds having one or more asymmetric carbons, and in the form of therapeutically acceptable inorganic or organic acid salts for the salifiable compounds.~~

2. (currently amended) An ~~compound~~analide derivative ~~corresponding to general formula I as claimed in claim 1,~~in accordance with claim 1 selected from the ~~following~~ group consisting of:

- (S)-2',3',5'-trimethyl-4'-hydroxy-α-dodecylsulfonyl-α-phenylacetanilide;
- (S)-2',3',5'-trimethyl-4'-hydroxy-α-(12,12-difluorododecylsulfonyl)-α-phenylacetanilide;
- 2',3',5'-trimethyl-4'-hydroxy-α-dodecylsulfonyl-α-fluoro-α-phenylacetanilide;
- 2',3',5'-trimethyl-4'-hydroxy-α-(2-dodecyl-2H-5-tetrazolyl)-α-phenylacetanilide;
- (+)-2',3',5'-trimethyl-4'-hydroxy-α-(2-dodecyl-2H-5-tetrazolyl) -α-phenylacetanilide;
- (+)-2',3',5'-trimethyl-4'-hydroxy-α-(2-hexyl-2H-5-tetrazolyl)-α-phenylacetanilide;
- 2',3',5'-trimethyl-4'-hydroxy-α-(2-decyl-2H-tetrazolyl)-α-phenylacetanilide;
- 2',3',5'-trimethyl-4'-hydroxy-α-[(2-(6,6-difluorohexyl)-2H-tetrazolyl]-α-phenylacetanilide;
- (+)-2',3',5'-trimethyl-4'-hydroxy-α-(2-dodecyl-2H-5-tetrazolyl)-α-fluoro-α-phenylacetanilide;
- 2',3',5'-trimethyl-4'-hydroxy-α-[2-(12,12-difluorododecyl)-2H-5-tetrazolyl]-α-fluoro-α-phenylacetanilide;
- 2',3',5',6'-tetramethyl-4'-amino-α-(2-dodecyl-2H-5-tetrazolyl)-α-fluoro-α-phenylacetanilide hydrochloride; and
- 2',3',5',6'-tetramethyl-4'-amino-α-(2-hexyl-2H-5-tetrazolyl)-α-phenylacetanilide hydrochloride; ~~and~~

enantiomers or stereoisomers of said analide derivatives, and pharmaceutically acceptable salts thereof.

3. (currently amended) ~~As a medicinal product, a compound of general formula I as claimed in either of claims 1 and 2, in particular as a medicinal product that is useful in~~ A

method for the treatment of ~~diseases such as~~ hypercholesterolemia or atherosclerosis comprising administering to a patient the analide derivative of claim 1.

4. (currently amended) A pharmaceutical composition~~, characterized in that it contains, besides~~ comprising an analide derivative of claim 1 and a pharmaceutically acceptable carrier~~, at least one compound of general formula I as claimed in either of claims 1 and 2~~.

5. (currently amended) ~~The use of compounds of formula I, as claimed in either of claims 1 and 2,~~A method for producing a medicinal products ~~intended for the treatment of diseases such as hypocholesterolemia or atherosclerosis~~comprising the step of combining the analide derivative of claim 1 and a pharmaceutically acceptable carrier.

6. (new) A method for the treatment of hypercholesterolemia or atherosclerosis comprising administering to a patient an analide derivative of claim 2.

7. (new) A pharmaceutical composition comprising the analide derivative of claim 2 and a pharmaceutically acceptable carrier.

8. (new) A composition comprising a mixture of two or more compounds of claim 1.

9. (new) A method of lowering blood cholesterol comprising administering to a patient the analide derivative of claim 1.

10. (new) A method of lowering blood cholesterol comprising administering to a patient the composition of claim 8.

11. (new) A method for producing a medicinal product comprising the step of combining the analide derivative of claim 2 and a pharmaceutically acceptable carrier.